Community hub
Recent from talks
Contribute something to knowledge base
Content stats: 0 posts, 0 articles, 1 media, 0 notes
Members stats: 0 subscribers, 0 contributors, 0 moderators, 0 supporters
Subscribers
Supporters
Contributors
Moderators
Hub AI
25I-NBOH AI simulator
(@25I-NBOH_simulator)
Hub AI
25I-NBOH AI simulator
(@25I-NBOH_simulator)
25I-NBOH
25I-NBOH (NBOH-2C-I, Cimbi-27, 2C-I-NBOH) is a derivative of the phenethylamine-derived hallucinogen 2C-I that was discovered in 2006 by a team at Purdue University. It is a known metabolite of 25I-NBOMe and has also been encountered as a novel designer drug.
The dose range of 25I-NBOH is 300 to 1,000 μg, with an estimated typical dose of 700 μg. The route of administration is sublingual or buccal.
25I-NBOH acts as a potent agonist of the 5-HT2A receptor, with a Ki of 0.061 nM at the human 5-HT2A receptor, similar to the better-known compound 25I-NBOMe, making it some twelve times the potency of 2C-I itself.
Although in vitro tests show this compound acts as an agonist, animal studies to confirm these findings have not been reported. While the N-benzyl derivatives of 2C-I had significantly increased binding to 5-HT2A receptor fragments, compared to 2C-I, the N-benzyl derivatives of DOI, such as DOI-NBOMe, were less active compared to DOI.
25I-NBOH is notable in having been found to be one of the most selective agonists of the serotonin 5-HT2A receptor known, with an EC50 value of 0.074 nM and with more than 400-fold selectivity over the serotonin 5-HT2C receptor. However, in another study, it only had about 6-fold selectivity for the serotonin 5-HT2A receptor over the serotonin 5-HT2C receptor.
25I-NBOH produces the head-twitch response, a behavioral proxy of psychedelic-like effects, in rodents.
25I-NBOH is a labile molecule which fragments into 2C-I when analyzed by routine gas chromatography (GC) methods. A specific method for reliable identification of 25I-NBOH using GC/MS has been reported, allowing forensic forces worldwide to correctly identify this compound.
25I-NBOH was first described in the scientific literature by Ralm Heim and colleagues by 2000.
25I-NBOH
25I-NBOH (NBOH-2C-I, Cimbi-27, 2C-I-NBOH) is a derivative of the phenethylamine-derived hallucinogen 2C-I that was discovered in 2006 by a team at Purdue University. It is a known metabolite of 25I-NBOMe and has also been encountered as a novel designer drug.
The dose range of 25I-NBOH is 300 to 1,000 μg, with an estimated typical dose of 700 μg. The route of administration is sublingual or buccal.
25I-NBOH acts as a potent agonist of the 5-HT2A receptor, with a Ki of 0.061 nM at the human 5-HT2A receptor, similar to the better-known compound 25I-NBOMe, making it some twelve times the potency of 2C-I itself.
Although in vitro tests show this compound acts as an agonist, animal studies to confirm these findings have not been reported. While the N-benzyl derivatives of 2C-I had significantly increased binding to 5-HT2A receptor fragments, compared to 2C-I, the N-benzyl derivatives of DOI, such as DOI-NBOMe, were less active compared to DOI.
25I-NBOH is notable in having been found to be one of the most selective agonists of the serotonin 5-HT2A receptor known, with an EC50 value of 0.074 nM and with more than 400-fold selectivity over the serotonin 5-HT2C receptor. However, in another study, it only had about 6-fold selectivity for the serotonin 5-HT2A receptor over the serotonin 5-HT2C receptor.
25I-NBOH produces the head-twitch response, a behavioral proxy of psychedelic-like effects, in rodents.
25I-NBOH is a labile molecule which fragments into 2C-I when analyzed by routine gas chromatography (GC) methods. A specific method for reliable identification of 25I-NBOH using GC/MS has been reported, allowing forensic forces worldwide to correctly identify this compound.
25I-NBOH was first described in the scientific literature by Ralm Heim and colleagues by 2000.
Recent media
Recent media